Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Capital Expenditures: 2019-2024

Historic Capital Expenditures for Cellebrite DI (CLBT) over the last 6 years, with Dec 2024 value amounting to $8.6 million.

  • Cellebrite DI's Capital Expenditures fell 82.53% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.4 million, marking a year-over-year decrease of 62.75%. This contributed to the annual value of $8.6 million for FY2024, which is 63.75% up from last year.
  • Cellebrite DI's Capital Expenditures amounted to $8.6 million in FY2024, which was up 63.75% from $5.2 million recorded in FY2023.
  • Cellebrite DI's Capital Expenditures' 5-year high stood at $8.6 million during FY2024, with a 5-year trough of $5.1 million in FY2021.
  • For the 3-year period, Cellebrite DI's Capital Expenditures averaged around $6.9 million, with its median value being $6.9 million (2022).
  • In the last 5 years, Cellebrite DI's Capital Expenditures decreased by 24.16% in 2023 and then skyrocketed by 63.75% in 2024.
  • Yearly analysis of 5 years shows Cellebrite DI's Capital Expenditures stood at $6.2 million in 2020, then declined by 17.31% to $5.1 million in 2021, then skyrocketed by 34.94% to $6.9 million in 2022, then decreased by 24.16% to $5.2 million in 2023, then spiked by 63.75% to $8.6 million in 2024.